Literature DB >> 19738171

Systemic inflammation and disease progression in Alzheimer disease.

C Holmes1, C Cunningham, E Zotova, J Woolford, C Dean, S Kerr, D Culliford, V H Perry.   

Abstract

BACKGROUND: Acute and chronic systemic inflammation are characterized by the systemic production of the proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha) that plays a role in immune to brain communication. Previous preclinical research shows that acute systemic inflammation contributes to an exacerbation of neurodegeneration by activation of primed microglial cells.
OBJECTIVE: To determine whether acute episodes of systemic inflammation associated with increased TNF-alpha would be associated with long-term cognitive decline in a prospective cohort study of subjects with Alzheimer disease.
METHODS: Three hundred community-dwelling subjects with mild to severe Alzheimer disease were cognitively assessed, and a blood sample was taken for systemic inflammatory markers. Each subject's main caregiver was interviewed to assess the presence of incident systemic inflammatory events. Assessments of both patient and caregiver were repeated at 2, 4, and 6 months.
RESULTS: Acute systemic inflammatory events, found in around half of all subjects, were associated with an increase in the serum levels of proinflammatory cytokine TNF-alpha and a 2-fold increase in the rate of cognitive decline over a 6-month period. High baseline levels of TNF-alpha were associated with a 4-fold increase in the rate of cognitive decline. Subjects who had low levels of serum TNF-alpha throughout the study showed no cognitive decline over the 6-month period.
CONCLUSIONS: Both acute and chronic systemic inflammation, associated with increases in serum tumor necrosis factor alpha, is associated with an increase in cognitive decline in Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19738171      PMCID: PMC2848584          DOI: 10.1212/WNL.0b013e3181b6bb95

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

1.  Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease.

Authors:  C Holmes; M El-Okl; A L Williams; C Cunningham; D Wilcockson; V H Perry
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

2.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

Review 3.  Aging and proinflammatory cytokines.

Authors:  H Bruunsgaard; M Pedersen; B K Pedersen
Journal:  Curr Opin Hematol       Date:  2001-05       Impact factor: 3.284

4.  Control of synaptic strength by glial TNFalpha.

Authors:  Eric C Beattie; David Stellwagen; Wade Morishita; Jacqueline C Bresnahan; Byeong Keun Ha; Mark Von Zastrow; Michael S Beattie; Robert C Malenka
Journal:  Science       Date:  2002-03-22       Impact factor: 47.728

5.  Delirium in older medical inpatients and subsequent cognitive and functional status: a prospective study.

Authors:  J McCusker; M Cole; N Dendukuri; E Belzile; F Primeau
Journal:  CMAJ       Date:  2001-09-04       Impact factor: 8.262

6.  Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?

Authors:  F Licastro; S Pedrini; L Caputo; G Annoni; L J Davis; C Ferri; V Casadei; L M Grimaldi
Journal:  J Neuroimmunol       Date:  2000-02-01       Impact factor: 3.478

7.  TNF-alpha stimulates caspase-3 activation and apoptotic cell death in primary septo-hippocampal cultures.

Authors:  X Zhao; B Bausano; B R Pike; J K Newcomb-Fernandez; K K Wang; E Shohami; N C Ringger; S M DeFord; D K Anderson; R L Hayes
Journal:  J Neurosci Res       Date:  2001-04-15       Impact factor: 4.164

8.  Inflammatory proteins in plasma and the risk of dementia: the rotterdam study.

Authors:  Marianne J Engelhart; Mirjam I Geerlings; John Meijer; Amanda Kiliaan; Annemieke Ruitenberg; John C van Swieten; Theo Stijnen; Albert Hofman; Jacqueline C M Witteman; Monique M B Breteler
Journal:  Arch Neurol       Date:  2004-05

9.  Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis.

Authors:  Minh Dang Nguyen; Thierry D'Aigle; Geneviève Gowing; Jean-Pierre Julien; Serge Rivest
Journal:  J Neurosci       Date:  2004-02-11       Impact factor: 6.167

10.  Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people.

Authors:  H Bruunsgaard; S Ladelund; A N Pedersen; M Schroll; T Jørgensen; B K Pedersen
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

View more
  370 in total

Review 1.  The immunology of neurodegeneration.

Authors:  Eva Czirr; Tony Wyss-Coray
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

2.  Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype.

Authors:  John M Ringman; David Elashoff; Daniel H Geschwind; Brian T Welsh; Karen H Gylys; Cathy Lee; Jeffrey L Cummings; Greg M Cole
Journal:  Arch Neurol       Date:  2012-06

Review 3.  Neuroprotective strategies involving ROS in Alzheimer disease.

Authors:  Magali Dumont; M Flint Beal
Journal:  Free Radic Biol Med       Date:  2010-12-01       Impact factor: 7.376

Review 4.  Anesthesia, surgery, illness and Alzheimer's disease.

Authors:  Roderic G Eckenhoff; Krzysztof F Laudansky
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-06-21       Impact factor: 5.067

Review 5.  Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease.

Authors:  Mrinmay Chakrabarti; Alexander J McDonald; J Will Reed; Melissa A Moss; Bhaskar C Das; Swapan K Ray
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

6.  Bacopa monnieri prevents colchicine-induced dementia by anti-inflammatory action.

Authors:  Neetu Saini; Devinder Singh; Rajat Sandhir
Journal:  Metab Brain Dis       Date:  2019-01-02       Impact factor: 3.584

Review 7.  Sexual dimorphism in predisposition to Alzheimer's disease.

Authors:  Daniel W Fisher; David A Bennett; Hongxin Dong
Journal:  Neurobiol Aging       Date:  2018-04-17       Impact factor: 4.673

Review 8.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

9.  Cognitive dysfunction with aging and the role of inflammation.

Authors:  Arthur A Simen; Kelly A Bordner; Mark P Martin; Lawrence A Moy; Lisa C Barry
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

10.  G protein-coupled receptor kinase 2 and group I metabotropic glutamate receptors mediate inflammation-induced sensitization to excitotoxic neurodegeneration.

Authors:  Vincent Degos; Stéphane Peineau; Cora Nijboer; Angela M Kaindl; Stéphanie Sigaut; Géraldine Favrais; Frank Plaisant; Natacha Teissier; Elodie Gouadon; Alain Lombet; Elie Saliba; Graham L Collingridge; Mervyn Maze; Ferdinando Nicoletti; Cobi Heijnen; Jean Mantz; Annemieke Kavelaars; Pierre Gressens
Journal:  Ann Neurol       Date:  2013-03-14       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.